Active Biotech to Present at the UBS 2008 Global Life Sciences Conference
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site.
The presentation will take place on September 23, at 1:00 pm US Eastern Time / 19:00 Central European Time.
About Active Biotech
Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 11:00 a.m. CET on September 17, 2008.
Active Biotech AB
Göran Forsberg, VP Communication & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00